Erythropoietin (EPO)

What it is

Erythropoietin (EPO) is a 30,400-dalton N-linked glycoprotein hormone produced primarily by peritubular fibroblasts in the renal cortex in adults and by hepatocytes during fetal life (PMID 12524467; PMID 26919118; PMID 58—PMID 10334664). EPO production is controlled at the transcriptional level: hypoxia stabilizes hypoxia-inducible factor (HIF, predominantly HIF-2) alpha subunits by inhibiting prolyl hydroxylases (PHD-1, -2, -3), allowing HIF to bind a 3' enhancer/hypoxia response element in the EPO gene and drive transcription (PMID 21078592; PMID 10334664; PMID 9793257). EPO binds its homodimeric receptor (EPO-R/EPO-R) on erythroid progenitor cells, inducing dimerization of the p66 chain, activation of JAK2 tyrosine kinase, and downstream phosphorylation of multiple pathways including Ras/MAPK, PI3K/Akt, and STAT 5a/5b transcription factors (PMID 12524467; PMID 58—PMID 10334664; PMID 15854305). EPO acts primarily as a survival factor, rescuing erythroid progenitors (BFU-E, CFU-E) from apoptosis and promoting their proliferation and differentiation into mature red blood cells (PMID 9793257; PMID 10334664; PMID 12524467). Beyond hematopoiesis, EPO also signals through a heterodimeric receptor complex (EPO-R/β-common receptor, CD131) expressed in non-hematopoietic tissues including brain, heart, skeletal muscle, kidney, and retina, mediating tissue-protective, anti-apoptotic, anti-inflammatory, antioxidant, angiogenic, and metabolic effects (PMID 34440909; PMID 41206499; PMID 39996752; PMID 21782802; PMID 16738535). EPO also regulates metabolism in adipose tissue, skeletal muscle, and liver through the EPO-EPOR-RUNX1 axis, enhancing lipolysis and inhibiting lipogenic gene expression. Concentration-dependent and context-dependent effects are noted: high-dose EPO may exacerbate systemic inflammation (e.g., in sepsis-associated encephalopathy), while moderate or low-dose EPO or derivatives (HBSP) may be neuroprotective.

Class: Glycoprotein hormone / hematopoietic growth factor / pleiotropic cytokine

What it's studied for

• Treatment of anemia in chronic kidney disease (renal anemia) Human observational
  • rHuEPO is used to treat anemia in patients with chronic renal failure; darbepoetin (NESP) maintains hemoglobin levels as effectively as rHuEPO at less frequent dosing. PMID 12524467 Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003.
  • EPO deficiency is the primary cause of anemia in chronic kidney disease; recombinant analogues can substitute for the hormone. PMID 21078592 Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011.
  • Treatment of renal anemia is restricted to EPO-stimulating agents; prolyl hydroxylase inhibitors show promising efficacy by stabilizing HIF and increasing EPO production. PMID 29655605 Shih HM et al. Physiology and pathophysiology of renal erythropoietin-producing cells. J Formos Med Assoc. 2018.
• Treatment of anemia in myelodysplastic syndromes (MDS) Human observational
  • Response to EPO (defined as Hb increase >15 g/L or eliminated transfusion requirements) was observed in 33% of 66 evaluable MDS patients. Baseline serum EPO level, marrow blast content, and transfusion need predicted response. Responders had significantly longer median survival (49 vs. 18 months). PMID 12068800 Wallvik J et al. Serum EPO levels correlate with survival and independently predict response to EPO treatment in MDS. Eur J Haematol. 2002.
• Treatment of chemotherapy-related anemia in cancer patients Human observational
  • EPO can improve quality of life and aid recovery from anemia post-chemotherapy and radiation; however, EPO therapy shortens survival in some cancers where antiapoptotic effect of EPO predominates directly in malignant cells. Therapeutic use requires prior investigation of EPO signaling on cancer cell proliferation. PMID 17385400 Sulkowska M et al. To give or not to give recombinant EPO to anemia endangered cancer patients. Prague Med Rep. 2006.
  • rHuEPO is used for anemia in nonmyeloid malignancies in patients treated with chemotherapeutic agents. PMID 12524467 Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003.
• Neuroprotection (ischemic stroke, brain injury, neurodegenerative disease) Mixed
  • EPO ameliorates or prevents neuronal injury through neuroprotective, anti-apoptotic, anti-inflammatory, antioxidant, angiogenic, neurogenic, and neurotrophic effects in cell culture and animal models. The clinical effectiveness of recombinant human Epo in ischemic stroke has been reported. PMID 15272145 Genc S et al. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci. 2004.
  • EPO administration provides neural protection in animal models of brain ischemia and trauma, reducing injury and damage. Therapeutic potential in brain ischemia/trauma and neurodegenerative diseases has shown promise in early clinical trial. PMID 17482474 Noguchi CT et al. Role of erythropoietin in the brain. Crit Rev Oncol Hematol. 2007.
  • Low sialic acid-containing EPO (Neuro EPO) shows neuroprotective effects similar to rHuEPO in ischemia models via intranasal route, potentially avoiding hematological side effects. PMID 22376076 Lagarto Parra A, Garcia Rodriguez JC. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment. CNS Agents Med Chem. 2012.
  • CSF EPO levels were lower in ALS patients compared to Alzheimer's disease and controls; lower CSF EPO correlated with more rapid disease progression, suggesting impaired EPO-associated neuroprotective capacity in ALS (human observational study, N=60 ALS patients). PMID 17368721 Brettschneider J et al. Cerebrospinal fluid EPO in amyotrophic lateral sclerosis. Neurosci Lett. 2007.
• Cytoprotection in kidney transplantation / ischemia-reperfusion injury Animal studies only
  • Protective, nonerythropoietic effects of EPO evident in preclinical renal ischemia/reperfusion models. Four clinical trials using high-dose EPO after renal transplantation did not show protective effect on short-term renal function and reported increased thrombosis risk. Nonerythropoietic EPO derivatives (carbamoylated PMID 23964738 van Rijt WG et al. Erythropoietin-mediated protection in kidney transplantation. Transplant Int. 2014.
• Therapeutic neovascularization / peripheral artery disease Animal studies only
  • EPO and G-CSF co-delivered via fibrin gel intramuscular injection in rat hindlimb ischemia model synergistically promoted neovascularization with limited systemic effects, superior to either agent alone on blood flow reperfusion, capillary density, and smooth muscle actin-positive vessel density. PMID 23294128 Chen F et al. Co-delivery of G-CSF and EPO released from fibrin gel for therapeutic neovascularization in rat hindlimb ischemia model. Microcirculation. 2013.
• Metabolic regulation (fat mass, glucose tolerance, energy homeostasis) Animal studies only
  • EPO enhances lipolysis while inhibiting lipogenic gene expression in white adipose tissue, brown adipose tissue, skeletal muscle, and liver via the EPO-EPOR-RUNX1 axis. The non-erythroid EPOR agonist ARA290 improved diet-induced obesity and glucose tolerance in animal models. Small clinical studies showed EPO treatment PMID 39996752 Yin W, Noguchi CT. The Role of Erythropoietin in Metabolic Regulation. Cells. 2025.
  • EPO increases POMC production in hypothalamic anorexigenic neurons and modulates ACTH secretion in the pituitary; EPO signaling contributes to the hypothalamic-pituitary axis as a regulator of glucose metabolism and energy homeostasis, mainly via fat tissue and hypothalamus responses (animal models). PMID 28629513 Dey S, Noguchi CT. Erythropoietin and Hypothalamic-Pituitary Axis. Vitam Horm. 2017.
• Ocular disorders (diabetic retinopathy, retinopathy of prematurity, glaucoma, AMD, optic neuritis, retinal detachment) Mixed
  • EPO and EPO receptors are present in retinal layers. EPO is proposed to have physiological roles in eye development and therapeutic/pathological roles in various ocular disorders. Review discusses clinical applications, modes of administration, EPO formulations, and ongoing clinical trials. PMID 27285322 Ding SLS et al. Revisiting the role of erythropoietin for treatment of ocular disorders. Eye. 2016.
• Lung disease cytoprotection Animal studies only
  • Review provides evidence that EPO and EPO-R are produced by lung tissue; EPO displays cytoprotective effects in several organs and may limit symptoms of acute and chronic lung diseases (preclinical/review-level evidence). PMID 33831836 Haine L et al. Cytoprotective effects of erythropoietin: What about the lung? Biomed Pharmacother. 2021.
• Anemia in patients with acute renal failure requiring renal replacement therapy Human observational
  • Retrospective cohort study (N=187). In propensity-adjusted analysis, EPO use did not decrease packed red blood cell transfusion, was not associated with renal recovery (OR 0.63, 95% CI 0.30–1.3), and in-hospital survival benefit was not significant. Authors call for RCT. PMID 16253718 Park J et al. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis. 2005.
• Doping / performance enhancement in sports (illicit use) Human observational
  • Excessive erythrocytosis from EPO use can lead to increased thrombogenicity, deep vein, coronary, and cerebral thromboses. Use banned by most sports-governing bodies. PMID 12524467 Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003.
  • EPO increases arterial O2 content by increasing red blood cell volume and decreasing plasma volume; elevates arterial blood pressure even in healthy subjects; metabolic, hormonal, and renal effects appear reversible and within physiologically acceptable limits in healthy volunteers. PMID 20807784 Lundby C, Olsen NV. Effects of recombinant human erythropoietin in normal humans. J Physiol. 2011.
• Sepsis-associated encephalopathy (SAE) / neuroinflammation Mixed
  • Retrospective analysis of 150 septic patients found elevated serum EPO levels were an independent risk factor for delirium. Animal studies showed low-dose EPO or HBSP attenuated neuroinflammation and neuronal apoptosis via microglial EPOR-βCR inhibiting TLR9/MyD88/NF-κB; high-dose EPO exacerbated systemic inflammation, PMID 41406833 Hu P et al. Exploring the EPO/EPOR-βCR/TLR9 pathways in sepsis-associated encephalopathy. Int Immunopharmacol. 2026.
• Cardioprotection / SUDEP prevention in refractory epilepsy Animal studies only
  • Review summarizes antiapoptotic role of EPO/EPO-R system in brain and heart under hypoxic conditions including epilepsy; high EPO-R expression in cardiac progenitor cells may contribute to myocardial regeneration. Proposed as novel therapeutic strategy for early treatment of SUDEP. PMID 32072891 Auzmendi J et al. EPO and EPO-Receptor System as Potential Actionable Mechanism for the Protection of Brain and Heart in Refractory Epilepsy and SUDEP. Curr Pharm Des. 2020.
• Bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (regenerative medicine) Animal studies only
  • EPO induces osteogenic and endothelial transdifferentiation of multipotent MSCs via EPO-R signaling, leading to bone remodeling, angiogenesis induction, and secretion of trophic factors. PMID 34440909 Tsiftsoglou AS. Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent MSCs. Cells. 2021.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• Hypertension: Common adverse effect of EPO therapy mediated by net vasoconstriction (altered nitric oxide, endothelin, prostaglanoids, sympathoadrenal, and renin-angiotensin pathways); occurs even in healthy subjects. PMID 29228345
• Thrombosis (deep vein, coronary, cerebral): Excessive erythrocytosis from EPO use increases thrombogenicity; high-dose EPO in renal transplantation clinical trials was associated with increased risk of thrombosis. PMID 12524467
• Increased thrombosis risk with high-dose EPO in four clinical trials of kidney transplantation patients. PMID 23964738
• Pure red cell aplasia (PRCA) due to anti-EPO antibody formation: Low-incidence but serious adverse event in dialysis patients; incidence ~0.29 per 1000 patient-years in one multicenter cohort. PMID 16105053
• EPO resistance/hyporesponse: Up to ~10% of patients receiving EPO are hyporesponsive, requiring large doses; EPO resistance associated with inflammation and increased mortality risk. PMID 18094727
• Higher average prior EPO dose associated with greater risk of death in hemodialysis patients. PMID 16377397
• Possible tumor growth promotion: EPO and EPO-R expressed in many tumor types; EPO may promote proliferation and survival of EPO-R-expressing cancer cells, shortening survival in some cancer types. PMID 17385400
• High-dose EPO in sepsis-associated encephalopathy exacerbated systemic inflammation, disrupted blood-brain barrier, and impaired cognition in animal models; elevated serum EPO was an independent risk factor for delirium in septic patients. PMID 41406833
• EPO elevates arterial blood pressure even in healthy subjects; hemodynamic effects require careful monitoring during administration. PMID 20807784
• Potential for hematological side effects (erythrocytosis, polycythemia) with systemic EPO administration; erythropoietic side effects are a recognized concern limiting neuroprotective use. PMID 22376076

Contraindications

• Caution in cancer patients with EPO-R-expressing tumors: EPO therapy may shorten survival in some cancers where antiapoptotic effect of EPO predominates in malignant cells; use requires prior investigation of EPO signaling on the specific cancer type. PMID 17385400
• High-dose EPO should be used with caution in sepsis-associated encephalopathy: high-dose EPO was associated with exacerbation of systemic inflammation and impaired cognition in septic patients and animal models. PMID 41406833
• EPO-induced PRCA: Development of anti-EPO antibodies leading to pure red cell aplasia is a recognized adverse event in patients on recombinant EPO; positive anti-EPO antibody testing is a contraindication to continued EPO therapy. PMID 16105053
• Athletes subject to anti-doping rules: Use of rHuEPO and darbepoetin to enhance athletic performance is officially banned by most sports-governing bodies. PMID 12524467